Katherine C Verbist

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4076842/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	RIPK1 Blocks Early Postnatal Lethality Mediated by Caspase-8 and RIPK3. Cell, 2014, 157, 1189-1202.	28.9	452
2	RIPK3 Activates Parallel Pathways of MLKL-Driven Necroptosis and FADD-Mediated Apoptosis to Protect against Influenza A Virus. Cell Host and Microbe, 2016, 20, 13-24.	11.0	299
3	Metabolic maintenance of cell asymmetry following division in activated T lymphocytes. Nature, 2016, 532, 389-393.	27.8	235
4	Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood, 2016, 127, 1666-1675.	1.4	207
5	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell, 2018, 33, 937-948.e8.	16.8	142
6	Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis. Blood, 2019, 134, 147-159.	1.4	99
7	Apoptosis-Inducing-Factor-Dependent Mitochondrial Function Is Required for T Cell but Not B Cell Function. Immunity, 2016, 44, 88-102.	14.3	69
8	JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. Blood, 2020, 136, 657-668.	1.4	50
9	Inhibition of diacylglycerol kinase α restores restimulation-induced cell death and reduces immunopathology in XLP-1. Science Translational Medicine, 2016, 8, 321ra7.	12.4	41
10	Synergistic Signaling of TLR and IFNα/β Facilitates Escape of IL-18 Expression from Endotoxin Tolerance. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 526-539.	5.6	38
11	Molecular basis of <i>ETV6</i> -mediated predisposition to childhood acute lymphoblastic leukemia. Blood, 2021, 137, 364-373.	1.4	37
12	T cell metabolism and the immune response. Seminars in Immunology, 2012, 24, 399-404.	5.6	29
13	Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome. Frontiers in Pharmacology, 2021, 12, 650295.	3.5	23
14	Expansion and CD2/CD3/CD28 stimulation enhance Th2 cytokine secretion of human invariant NKT cells with retained anti-tumor cytotoxicity. Cytotherapy, 2020, 22, 276-290.	0.7	7
15	Germline Genetic Variation in IKZF1 and Predisposition to Childhood Acute Lymphoblastic Leukemia. Blood, 2016, 128, LBA-2-LBA-2.	1.4	3
16	Combined Treatment with Ruxolitinib and Dexamethasone Curtails Inflammation and Lessens Disease in Preclinical Studies of Hemophagocytic Lymphohistiocytosis. Blood, 2016, 128, 4894-4894.	1.4	1
17	The Combination of Dexamethasone and Ruxolitinib Synergistically Attenuates Disease Manifestations in a Preclinical Model of Hemophagocytic Lymphohistiocytosis. Blood, 2019, 134, 81-81.	1.4	1
18	Therapeutic Candidate Alpn-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Human/NSG Mouse Xenograft Graft Vs. Host Disease (GvHD) in a Dose Ranging Study and Reduces Disease Activity in a Mouse Model of Hemophagocytic Lymphohistiocytosis (HLH). Blood. 2018. 132. 2037-2037.	1.4	0

#	Article	IF	CITATIONS
19	Translationally Relevant Oral Ruxolitinib Dosing Reduces Inflammation and Ameliorates Disease in Murine Models of Hemophagocytic Lymphohistiocytosis. Blood, 2020, 136, 21-21.	1.4	0